Together with researchers from the University of Washington, TropIQ was awarded 1.3 million USD from the Bill & Melinda Gates Foundation to find new mosquito repellents and thus aid the fight against mosquito-borne diseases such as malaria, dengue and Zika. The project combines artificial intelligence, high-throughput mosquito testing and neurophysiological studies of mosquitos’ sensory…

The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further advocates target based drug discovery over phenotypical screening approaches. Read more here

Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria drug. read more here

TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation to advance the development of novel anti-malarial drugs. This review describes the consortiums mission and their accomplishments to date. read more here

In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read more here

To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was generated. This parasite performed comparable to wild type P. falciparum and therefore supports its use in optimizing whole parasite vaccine studies. read more here

CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time Nijmegen and San Francisco — October 8, 2020 TropIQ Health Sciences, a  biotechnology social enterprise with a dual purpose to provide enabling technologies and expertise in drug discovery as well as to develop new drugs for the treatment of…

Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length PfCSP which could expedite malaria vaccine development. Read more here.

Dr. Sheshachalam has joined the team as a Scientist. He is an experienced cell biologist with a broad expertise in immunology, molecular biology and drug discovery. He obtained his PhD at the University of Alberta, Canada and previously worked in a drug company in India before joining us at TropIQ.

Dutch national radio (BNR) has conducted an interview with TropIQ’s CEO Koen Dechering on the recently published novel malaria drug candidate (see publication here). Listen to the interview here (in dutch).